[1] |
FAN Liping, LU Shu, CAI Yueping, WAN Yuxiang, SUN Huiyuan.
Kanglaite Combined with Gefitinib for Mid-Late Stage Lung Cancer:a Meta-Analysis and Trial Sequential Analysis
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 316-323.
|
[2] |
WEI Fenfang, WU Wenyu, LI Limin, TANG Biyu, WU Jianru.
Foreign methods for benefit-risk assessment of pharmaceutical products
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 900-905.
|
[3] |
WANG Yi, REN Jingtian.
Evaluation and significance of benefit-risk analysis of benzbromarone-induced liver injury
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(2): 189-192.
|
[4] |
GUO Zhijian, HU Fangyuan, ZHENG Yi, LIANG Jizhou, XU Jinfang, GUO Xiaojing, YE Xiaofei, HE Jia.
Current Research on Quantitative Drug Benefit-Risk Assessment Methods and Its Englightenment
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(7): 649-654.
|
[5] |
LIAO Yufang, YUE Jiannong, SI Ke.
One Case of Severe Serum Transaminase Elevation with Acute Cholecystitis Induced by Gefitinib Tablets
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(6): 584-587.
|
[6] |
CAO Hongli, YU Panpan, YANG Jing, XI Jianing.
Effect of Gefitinib Combined with Paclitaxel on Quality of Life and Survival in Patients with NSCLC
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(6): 562-565.
|
[7] |
JIANG Hao, ZHANG Zhiqi, ZHANG Bing, ZHANG Xiaomeng, GENG Kexin.
Benefit-Risk Assessment of Mylabris Preparations in the Treatment of Primary Hepatic Carcinoma
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(6): 525-531.
|
[8] |
ZHANG Xiaomeng, ZHANG Bing, ZHANG Dan, LIN Zhijian.
Exploration the "Risk-Benefit Threshold" of Chinese herbs with Acrid, Hot and Toxic Properties
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(6): 514-519.
|
[9] |
LIU Chunguang, LIANG Gongshan, XU Changqing.
Research Progress in Methods of Risk & Benefit Assessment of Vaccines
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(11): 1097-1100.
|
[10] |
FAN Pengli, LU Lele, WANG Yimeng, LIU Yinping.
Analysis of One Case of purpura fulminans Induced by Gefitinib Tablets
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(7): 441-443.
|
[11] |
ZHU Qian, SHAN Qiuyue, YUAN Ye, FANG Wei, SONG Hong, LIANG Jinjin, CAO Tiejun.
Analysis of Differences between Periodic Safety Update Reports for Marketed Drugs in China and Periodic Benefit-risk Evaluation Report in ICH
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(6): 357-360.
|
[12] |
ZHANG Xiao-meng, LIN Zhi-jian, ZHANG Bing, LI Min.
Comparison of Aconitum with Tripterygium in Treatment of Axial Spondyloarthritis: A Benefit-risk Assessment
[J]. Chinese Journal of Pharmacovigilance, 2018, 15(2): 103-109.
|
[13] |
BIE Zhi-xin, DING Li.
Clinical Characteristics of Patients with Interstitial Lung Disease Induced by Gefitinib and Erlotinib
[J]. Chinese Journal of Pharmacovigilance, 2017, 14(5): 309-312.
|
[14] |
XIONG Wei-yi, DONG Duo.
Multiple Criteria Decision Analysis-Based Methodologies for Pharmaceutical Product Risk-Benefit Assessment
[J]. Chinese Journal of Pharmacovigilance, 2017, 14(12): 752-754.
|
[15] |
XIA Hui-hong.
Literature Analysis of 82 Cases of Adverse Drug Reactions Induced by Gefitinib
[J]. Chinese Journal of Pharmacovigilance, 2016, 13(2): 98-102.
|